The Sunshine Act: Where it stands, where it s going and compliance implementation

Similar documents
State Laws: Preemption, Enforcement, and Continued Requirements

Frequently Asked Questions

Aggregate Spend: An Update on State Laws and Regulations

Web Seminar. Physician Payments in the "Sunshine": Implications of CMS Regulations for Business and the Future of American Health Care.

Pharmaceutical Compliance Congress: State of the States

FACT SHEET. The Physician Payments Sunshine Act: CMS Proposed Rule

Understanding the Forces Driving Disclosure

KEY CHANGES IN THE FINAL PHYSICIAN PAYMENT SUNSHINE ACT REGULATIONS. Association of Corporate Counsel Legal Quick Hit May 30, 2013.

Federal and State Transparency Meeting Obligations and Managing Risks

STATE TRANSPARENCY AND GIFT BAN STATUTES

Physician Payment Sunshine Provisions in Healthcare Reform Prepared by AAMC Government Relations Revised May 28, 2010

Association of Corporate Counsel January 2012 Teleconference CMS Finally Issues Proposed Sunshine Act Regulations

Client Alert. CMS Announces Final Regulations Interpreting the Physician Payment Sunshine Act. A. Definitions and Exclusions

Physician Payments Sunshine Act Proposed Rule Published

Shedding Light on the Sunshine Act

Open Payments Law Overview. University of Alabama at Birmingham University Compliance Office

Know, Prepare and Comply with the Sunshine Act Phase 2. John A. Murphy, III, Assistant General Counsel PhRMA August 26, 2014

PHYSICIAN PAYMENTS SUNSHINE ACT (OPEN PAYMENTS) Mary Evelyn Armstrong MA, CRA Conflict of Interest Officer

FOR PHYSICIANS. CMS will collect the data annually, aggregate it, and publish it on a public website.

The Physician Payments Sunshine Law and you: Building stronger industry - physician interactions

Physician-Vendor Relationship Compliance: Minimizing False Claims, Anti-Kickback Risks

Transparency reports (Sunshine Act)

Physician Payment Transparency Provisions of the Affordable Care Act Sunshine 101

Patient Protection and Affordable Care Act (P.L ) Titles VI through X

CMS ISSUES FINAL RULE FOR IMPLEMENTING SUNSHINE ACT. Executive Summary

Welcome to the Lex Mundi Learning Network. Understanding the New U.S. Sunshine Act and Its Impact on Health Care Providers and Industry

The Impact of the Fraud and Abuse Laws on Pharmaceutical Advertising and Marketing Compliance: A Manufacturer s Perspective

SIDE-BY-SIDE OF THE PHYSICIAN PAYMENTS SUNSHINE ACT

Industry Funding of Continuing Medical Education

Section 6004: Prescription Drug Sample Transparency. Section 6005: Pharmacy Benefit Managers Transparency Requirements

Jim Frizzera, Principal Health Management Associates

Strategic and Operational Challenges Resulting from the New PPACA

Aetna Medicare 2013 Benefits at a Glance

Do Start Believin': The Life Sciences Industry's Journey to Global Transparency

Sunshine and Aggregate Spend

Marilyn Tavenner, CMS Administrator Don Moulds, Acting Assistant Secretary for Planning and Evaluation

2014 SUMMARY OF BENEFITS

CHAPTER 6. The Economic Contribution of Hospitals

Physician Payments Sunshine Act Final Rule ACA Section 6002

REPORT OF THE COUNCIL ON MEDICAL SERVICE. (J. Leonard Lichtenfeld, MD, Chair)

ANCILLARY services: How to Stay Out of Trouble. The neurosurgical minefield Informed consent

Proposed MAC Legislation May Increase Costs Of Affected Generic Drugs By More Than 50 Percent. Prepared for

CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER

MEDICARE PART D SPOTLIGHT

Proposed MAC Legislation May Increase Costs of Affected Generic Drugs By More Than 50 Percent. Prepared for

Highlights. Percent of States with a Decrease in MH Expenditures from Prior Year: FY2001 to 2010

CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER

Health Reform & Immuniza3ons in 2014

Physician Payments Sunshine Provisions in Healthcare Reform Tracking and Monitoring Spending on Healthcare Professionals and Organizations

HealthSpring Prescription Drug Plan (PDP) 2013 Summary of Benefits S5932

Government, Industry and Health Profession Compliance Guidance: Welcome to the Era of Ethics and Transparency

Latham & Watkins Corporate and Litigation Departments. CMS Issues Proposed Regulations Interpreting the Physician Payment Sunshine Act

Open Payments An Explanation of Section 6002 of the Affordable Care Act

Healthcare Regulatory Issues We Wish We d Never Heard of

Legal Considerations for Patient Assistance Programs

WELLCARE WINS BID IN EVERY REGION FOR 2007 AND INTRODUCES CLASSIC PLAN WITH LOWER PLAN PREMIUMS

Employees may incur and/or submit for reimbursement only those business expenses that are consistent with Cardinal Health policy.

Telemedicine: Has the Future of Healthcare Delivery Arrived? Nathaniel M. Lacktman

CBI PAP LEGAL UPDATE MEDICARE & MEDICAID A REVIEW OF COMPLIANCE WITH GOVERNMENT PROGRAMS. September 26, Sarah difrancesca Partner Cooley LLP

Title Final Sunshine Act Arrives: Now the Hard Part

Required Training Completion Date. Asset Protection Reciprocity

Shedding Light on the U.S. and French Sunshine Laws

Table PDENT-CH (continued) This measure identifies the percentage of children ages 1 to 20 who are covered by Medicaid or CHIP Medicaid Expansion

Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis

COMPLIANCE WITH PATIENT ASSISTANCE PROGRAMS AND CO-PAY CARDS. Judd Katz JD MHA November 2016

CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPEN PAYMENT FREQUENTLY ASKED QUESTIONS (FAQ) TRACKER. June attorney advertisement

Pharmaceuticals: Can or Should We Do Anything About Rising Drug Costs? Caroline F. Pearson

Medicare Part D: A First Look at Plan Offerings in 2014

HCCA CLINICAL PRACTICE COMPLIANCE CONFERENCE

Medicaid & CHIP: February 2014 Monthly Applications, Eligibility Determinations, and Enrollment Report April 4, 2014

CRS Report for Congress

MEDICARE PART D SPOTLIGHT

Gifts to Referral Sources. Kim C. Stanger (11-17)

340B Program Update & Recommendations for Monitoring Program Compliance October

Affordable Care Act: what tax directors need to know. 14 May 2013

Product Reimbursement Services and Patient Assistance Programs KATHY CHAURETTE ALESSANDRO MARTUSCELLI

medicaid a n d t h e How will the Medicaid Expansion for Adults Impact Eligibility and Coverage? Key Findings in Brief

Thank you for downloading this patient assistance document from NeedyMeds. We hope this program will help you get the medicine you need.

Out-of-Network Billing

Status: Time: 12:00 pm. Date: 3/19/10

Cost Report Compliance Issues for Critical Access Hospitals

If you have any other questions, please feel free to call us at MEDICARE ( ). Sincerely,

Center on Budget and Policy Priorities. cbpp.org

kaiser medicaid and the uninsured commission on The Cost and Coverage Implications of the ACA Medicaid Expansion: National and State-by-State Analysis

2013 Summary of Benefits

36 Million Without Health Insurance in 2014; Decreases in Uninsurance Between 2013 and 2014 Varied by State

NeedyMeds

Bill Moran and Betta Sherman

The Impact of the Finalized Modifications to the Stark Law

Medicare and Patient Assistance

Federal Spending on Brand Pharmaceuticals. April 2011

MEMORANDUM. Bob Saner, MGMA Washington Counsel and Johanna Michaels Kreisel, Attorneys in the Powers Law Firm

MARKET TRENDS: MEDICARE SUPPLEMENT. Gorman Health Group, LLC

Frequently Asked Questions (FAQs) regarding the. National Physician Payment Transparency Program (Open Payments)

Compliance and Fraud, Waste, and Abuse Awareness Training. First Tier, Downstream, and Related Entities

Data Note: What if Per Enrollee Medicaid Spending Growth Had Been Limited to CPI-M from ?

2012 Summary of Benefits

Sleaze, Graft and Corruption in Surgical Pathology Version 3.0

Supplemental Special Advisory Bulletin: Independent Charity. Patients who cannot afford their cost-sharing obligations

How Pharma Cos. Can Lessen The Risk Of Gov't Action

Transcription:

The Sunshine Act: Where it stands, where it s going and compliance implementation PRESENTED BY: Stacey A. Filice Jazz Pharmaceuticals

Disclaimer slide The views expressed in this presentation are my own based on my personal experience and do not necessarily represent the views of Jazz Pharmaceuticals or its employees. This presentation is solely intended for educational purposes and provides only a general description of upcoming Sunshine Act reporting requirements and various state gift reporting laws. For a complete description, please consult the relevant federal and state regulatory statutes. Nothing in this presentation nor anything I discuss in Q&A constitutes legal advice, and you should not rely legally on any information that I provide. I make no warranty, express or implied, with respect to such information and disclaim all liability resulting from any use of or reliance on this information. 2

Objectives and Agenda Objectives Briefly outline each state law and the Sunshine Act Small group discussions regarding questions, challenges and best practices Agenda State overview Sunshine Act overview High level comparison of state laws and Sunshine Act Discuss challenges Q&A 3

California - Compliance Program Law Annual spending limit on gifts Company established Per day spending limit No requirement Requirement to adopt Comprehensive Compliance Program consistent with Office of Inspector General (OIG) guidance No reporting required Publicly available declaration of compliance Annually How can you comfortably make this declaration? Drug Sample Reporting - None 4

Connecticut - Code of Conduct & Compliance Program Law Adoption of a Code of Conduct that is consistent with and incorporates the requirements of the PhRMA Code. Companies must also have a comprehensive compliance program consistent with OIG guidance Annual spending limit on gifts None Per day spending limit None No reporting required Drug Sample Reporting None 5

District of Columbia - Marketing Costs Disclosure Annual spending limit on gifts to Healthcare Professionals (HCPs) None Per day spending limit None, but gifts greater than $25 per day are reportable Annual reporting required Drug Sample Reporting None DC Safe RX Licensure requirement 6

Massachusetts - Marketing Code of Conduct Adopt a Code of Conduct in compliance with requirements of 105 C.M.R. 970.000 Annual certification of audit of compliance with 105 C.M.R. 970.000 7

Massachusetts - Payment Disclosure Law & Gift Ban Annual spending limit on gifts to HCPs None Gift Ban Per day spending limit None, but Allowable Expenditures greater than $50 per day are reportable Pre-July 2012 - Annual aggregate reporting of payments to each individual or office and the number of events reflected Post July 2012 waiting for final regs Quarterly reporting Change in Gift Ban Drug Sample Reporting None 8

Minnesota - Gift Prohibition Gift Prohibition Certain payments and gifts totaling over $50 per year per practitioner Annual spending limit on gifts to Practitioners How can you ensure that company-wide spend on a practitioner does not exceed this amount? Per day spending limit None Annual Reporting certain payments (not considered gifts or are non-prohibited gifts) if annual aggregate per practitioner exceeds $100 Drug Sample Reporting None 9

Nevada - Marketing Code of Conduct & Compliance Program Law Adoption of a Marketing Code of Conduct, Compliance training program and compliance officer Annual spending limit on gifts None Per day spending limit None Annual certification of audit for compliance with code of conduct Drug Sample Reporting - None 10

Vermont - Marketing Costs Disclosure Law Gift ban includes any HCP licensed in the state and members of the Green Mountain Care Board Annual spending limit - None Per day spending limit None Annual Reporting Allowable Gift & Expenditures if annual aggregate per practitioner exceeds $100 Drug Sample Reporting drug samples and coupons, vouchers, Point of Sale cards, etc. 11

West Virginia - Advertising Costs Reporting Law Annual spending limit on gifts None Per day spending limit None Annual reporting required Aggregate marketing costs Reportable Expenses over $99.99 Drug Sample Reporting None 12

Patient Protection & Affordable Care Act Two Parts to discuss (1) Federal Prescription Drug Sample Transparency & (2) Federal Physician Payment Sunshine Act Federal Physician Payment Sunshine Act Tracking and reporting transfers of value to physicians and teaching hospitals that either (1) are over $10, or (2) exceed an annual aggregate of $100 per physician or institution Reporting: the name of the covered recipient; the business address of the covered recipient; the amount of the payment or transfer of value; the dates on which the payment or transfer of value was provided to the covered recipient; a description of the form of the payment or transfer of value (e.g., cash, in-kind item, stock, etc.); a description of the nature of the payment or transfer of value (e.g., consulting fees, food, travel, etc.); the name of the product to which the payment relates (if the payment is related to a specific product) Awaiting final regulations from Centers for Medicare and Medicaid Services (CMS) Tracking to begin TBD First reporting due - TBD State law preemption not really 13

Patient Protection & Affordable Care Act, cont d. Federal Prescription Drug Sample Transparency First report due April 1, 2012 grace period until October 1, 2012 to ensure quality reporting submit annual reports to FDA through electronic submissions gateway submit the identity and quantity of drug samples requested and the identity and quantity of drug samples distributed under Section 503 of the Prescription Drug Marketing Act aggregated by: the name, address, professional designation, and signature of the practitioner making the request or of any individual who makes or signs for the request on behalf of the practitioner 14

State and Federal Overview Compliance Program and/or Code of Conduct Spending Limits CA X X CT DC X Gi8 Ban Annual Gi8/ Payment / other Repor>ng MA X X X MN X X X NV X X Drug Sample Repor>ng VT X X X WV Federal X X X 15

Challenges in Tracking and Reporting States have different definitions of what is a gift States and Federal have different rules around reporting of honoraria or consulting fees, marketing costs, aggregate costs of employees no consistency Different definitions of HCP and/or who is subject to the reporting requirements Indirect payments who gives you this information? Is it reliable? Is your current process for collection scalable for Sunshine? Internal systems capturing the right information in a meaningful way? 16

Other Challenges Relationships with HCPs Information is posted publicly who is looking? Company growth Organizational changes (ie, mergers, acquisitions) What is the legal structure? How to report for multiple entities? How do you know where all relevant data is? Who can tell you? How to merge multiple systems? 17

Q&A Did any questions come from your group discussions that we can open up to the larger group? 18

Thank you! 19

Wednesday through Friday September 19-21, 2012